JP Morgan Initiates Coverage On IGM Biosciences with Neutral Rating, Announces Price Target of $27

JP Morgan analyst Eric Joseph initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Neutral rating and announces Price Target of $27.

byBenzinga Newsdesk

October 17, 2022

1 minute read

JP Morgan analyst Eric Joseph initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Neutral rating and announces Price Target of $27.

Why Datto Shares Are Trading Higher Today

By Anusuya Lahiri

Today, 5:46 AM

Software maker Datto Holding Corp (NYSE:MSP) weighed strategic options, including a potential sale after receiving takeover interest from PE firms, Bloomberg…

MSP

RBC Capital Maintains Outperform on Major Drilling Group Intl, Raises Price Target to C$15

By Benzinga Newsdesk

Today, 5:46 AM

RBC Capital analyst Sam Crittenden maintains Major Drilling Group Intl (TSX:MDI) with a Outperform and raises the price target from C$14 to C$15.

TSX:MDI

UBS Sees 10% Upside In Albertsons

By Shivani Kumaresan

Today, 5:46 AM

Albertsons Companies Inc (NYSE:ACI) has launched two new digital offerings, namely, Meal Planning and Schedule & Save. The new features…

ACI

SEC Chair Gensler Says Crypto Exchanges ‘Operating Outside Of The Law’: What You Need To Know

By Wayne Duggan

Today, 5:46 AM

Securities and Exchange Commission Chair Gary Gensler spoke at the Piper Sandler Global Exchange and Fintech Conference on Wednesday. One of the topics Gensler discussed in the Q&A session was cryptocurrency regulation.

BTC

JP Morgan Initiates Coverage On IGM Biosciences with Neutral Rating, Announces Price Target of $27

Related Posts

Why Datto Shares Are Trading Higher Today

RBC Capital Maintains Outperform on Major Drilling Group Intl, Raises Price Target to C$15

UBS Sees 10% Upside In Albertsons

SEC Chair Gensler Says Crypto Exchanges ‘Operating Outside Of The Law’: What You Need To Know